Cardiovascular follow‐up of patients with prostatic cancer treated with single‐drug polyestradiol phosphate

Publisher Website
Google Scholar
Abstract
Thirty‐eight patients with cancer of the prostate were treated with strict parenteral estrogen in the form of monthly polyestradiol phosphate injections–160 mg, 240 mg, and 320 mg—in this nonrandomized study. In contrast to studies with oral estrogens, there have been no cardiovascular complications at a mean follow‐up of 12.9 ± 0.7 months (SEM). Twenty‐nine of the 38 patients (76%) have responded to therapy.